Article Details
Retrieved on: 2025-01-02 14:21:28
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article highlights Capricor Therapeutics’ submission of a Biologics License Application for deramiocel, a cell therapy targeting Duchenne muscular dystrophy (DMD) cardiomyopathy—primarily utilizing extracellular vesicles for regenerative treatment, significant in regenerative therapy advancement.
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here